Guinea vs Mozambique: Average cost of drugs for extensively drug-resistant tuberculosis
Guinea
5,356 constant 2022 US$
in 2024
Mozambique
5,675 constant 2022 US$
in 2024
Guinea rank
9th
Mozambique rank
7th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guinea
- Mozambique
How they compare
Mozambique currently reports 5,675 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea, a difference of 319 constant 2022 US$.
That makes Mozambique's figure about 1.1 times Guinea's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Guinea ahead.
Guinea ranks 9th and Mozambique ranks 7th of 56 countries.
Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 8,964 constant 2022 US$ | 3,564 constant 2022 US$ | 5,400 constant 2022 US$ | Guinea |
| 2020s | 8,060 constant 2022 US$ | 4,938 constant 2022 US$ | 3,123 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guinea or Mozambique?
- Mozambique, at 5,675 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guinea and Mozambique?
- 319 constant 2022 US$, with Mozambique ahead.
- How many years of comparable data are there for Guinea and Mozambique?
- 8 years are reported by both, from 2017 to 2024.
- How do Guinea and Mozambique rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guinea ranks 9th and Mozambique ranks 7th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.